NEW RAY MEDICINE INTERNATIONAL HOLDING LIMITED will hold its Annual General Meeting (AGM) on 18 June 2026 at 9:00 a.m. in Central, Hong Kong. Key resolutions and timetable details are as follows:
Share Issuance & Repurchase Authorities • General Mandate – Directors seek authority to issue, allot or otherwise deal with new shares up to 20% of the issued share capital on the AGM date, equivalent to a maximum of 40.12 million shares based on the current 200.62 million shares outstanding. • Repurchase Mandate – Board requests power to buy back up to 10% of issued shares, or 20.06 million shares. • Extension Mandate – Shares repurchased under the above authority may, if approved, be added to the issuance capacity, potentially expanding the headroom beyond 20%.
Director Re-election • Executive Chair & CEO Ms Wang Qiuqin and Independent Non-executive Director Mr Sy Lai Yin, Sunny will retire by rotation and stand for re-election. The Nomination Committee supports their re-appointment, citing experience and independence.
Adoption of New Bye-laws • The Board proposes a third amended and restated set of Bye-laws to align with updated Listing Rules, Bermuda law and the forthcoming Hong Kong uncertificated securities market (USM). Changes cover electronic share registration, treasury shares, electronic communications and other housekeeping modifications.
Share Capital & Repurchase Rationale • As at 17 April 2026, the company had 200.62 million shares in issue and held no treasury shares. • Management believes share buybacks could enhance net asset value and earnings per share when market conditions permit. The Board does not intend to execute repurchases that would reduce public float below 25%.
AGM Logistics & Key Dates • Register closure: 15–18 June 2026 (both days inclusive); last day to lodge transfers is 12 June 2026 at 4:30 p.m. • Proxy deadline: 16 June 2026 at 9:00 a.m. • Record date for AGM voting: 18 June 2026.
Audit & Other Business • Re-appointment of Moore CPA Limited as external auditor for FY2026 and authorisation for the Board to fix its remuneration will be put to vote.
No shareholder is required to abstain from voting on any proposed resolutions. Directors and core connected persons have indicated no present intention to dispose of shares under the proposed buyback mandate.